Know Cancer

or
forgot password

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose-Titration Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia


Phase 3
2 Years
17 Years
Open (Enrolling)
Both
Hyponatremia

Thank you

Trial Information

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose-Titration Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia


A 3:1 randomization between conivaptan and placebo will be implemented and randomization
will be further stratified in a 1:1:2 ratio for age groups: 2-5 years, 6-10 years, and 11-17
years.

Subjects will need to remain hospitalized for the 48-hour Treatment Period through Hour 96
(Day 4). There will be a follow-up safety visit on Day 9 or day of hospital discharge,
whichever occurs first. There is a final follow-up phone call at Day 32 to assess if any
serious adverse events have occurred since hospital discharge.


Inclusion Criteria:



- Subject is euvolemic or hypervolemic hyponatremia upon clinical presentation

- Subject has serum sodium value ≥ 115 mEq/L (115 mmol/L) and < 130 mEq/L (130 mmol/L)
during the 24 hours preceding inclusion into the study

- Female subject of childbearing potential must have a negative serum pregnancy test
and must be premenarchal, surgically sterile or must practice a method of birth
control

Exclusion Criteria:

- Female subject is pregnant or lactating

- Subject has a body mass index (BMI) < the 3rd percentile or > the 97th percentile for
their age and stature according to the World Health Organization; Body mass
index-for-age percentiles charts for boys and girls ages 2 to 20

- Subject has clinical evidence of volume depletion, dehydration or hypovolemia

- Subject with hypovolemic hyponatremia or transient causes of hyponatremia that are
likely to resolve during the time of study participation

- Subjects with a cause of hyponatremia that is most appropriately corrected by
alternative therapies

- Subject is expected to receive emergent treatment for hyponatremia during the
treatment period of the study

- Subject has clinical evidence of hypotension

- Subject has uncontrolled hypertension > the 99th percentile for their age

- Subject has uncontrolled bradyarrhythmias or tachyarrhythmias requiring emergent
pacemaker placement or treatment

- Subject has untreated severe hypothyroidism, hyperthyroidism or adrenal insufficiency

- Subject has known urinary outflow obstruction, unless subject is, or can be
catheterized during the study

- Subject has estimated creatinine clearance < 30 mL/min during the seven days prior to
study drug administration

- Subject has alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
elevations > 3 times the upper limit of normal reference range during the seven days
prior to study drug administration

- Subject has serum albumin ≤ 1.5 g/dL during the seven days prior to study drug
administration

- Subject has white blood cell count (WBC) < 3000/micro-liter documented any time
during seven days prior to study drug administration or anticipated drop in WBC to <
3000/micro-liter during the period of the study due to chemotherapy

- Subject currently has unstable hepatic function or a history of hepatic
encephalopathy, or bleeding esophageal varices within the last 3 months

- Subject has acute heart failure. Prior history of heart failure is allowed if there
are no current signs/symptoms

- Subject has a non-fasting blood glucose value ≥ 275 mg/dL

- Subject requires or is suspected to require treatment with potent inhibitors or
potent inducers of CYP3A4

- Subject was administered hypertonic saline or oral salt supplement within 24 hours
prior to study drug administration

- Subject requires the use of medications used in the treatment of Syndrome of
Inappropriate Antidiuretic Hormone Secretion (SIADH): including lithium salts, urea
or demeclocycline during the week prior to screening and throughout the study drug
treatment period

- Subject has any condition that may interfere with treatment or evaluation of safety

- Subject has received investigational therapy (including placebo) within 28 days or 5
half lives, whichever is longer

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Mean change from baseline to Hour 48 in serum sodium as compared to placebo

Outcome Time Frame:

Baseline and Hour 48

Safety Issue:

No

Principal Investigator

Medical Director

Investigator Role:

Study Director

Investigator Affiliation:

Astellas Pharma Global Development

Authority:

United States: Food and Drug Administration

Study ID:

087-CL-096

NCT ID:

NCT01451411

Start Date:

February 2012

Completion Date:

February 2016

Related Keywords:

  • Hyponatremia
  • Serum Sodium
  • Euvolemia
  • Hypervolemia
  • Vaprisol®
  • Conivaptan
  • YM087
  • Hyponatremia

Name

Location

Medical University of South CarolinaCharleston, South Carolina  29425-0721
Hackensack University Medical CenterHackensack, New Jersey  07601
University of KentuckyLexington, Kentucky  40536-0098
Robert Wood Johnson University HospitalNew Brunswick, New Jersey  08903
Arkansas Children's Hospital Research InstituteLittle Rock, Arkansas  72202
Riley Children's HospitalIndianapolis, Indiana  46202
Saint Louis Children's HospitalSaint Louis, Missouri  63110
Children's Hospital of New York - PresbyterianNew York, New York  10032